LAUSR

Doravirine (DOR) efficacy and safety has been evaluated in adult naïve or treated patients starting a DOR-based regimen between 09/15/2019 and 12/31/2020. Medical history and examination, laboratory results, tolerance were assessed during the 48 weeks of follow-up. Among the 77 patients included, virological control (VC) was noticed for 66 at baseline. Median age was 51 years, and 62% were men. The most common reason for initiating a DOR-based therapy was toxicity (44; 67%) and, especially, weight gain. A virological suppression was maintained in 55 (83%) of the VC-group and noticed in 9 (82%) of the non-VC patients at W48, by intention to treat analysis. In on treatment analysis, 98% and 100% patients achieved VS in the VC and non-VC groups respectively. The renal and metabolic tolerance were good. DOR-based regimens appear to be a safe and relevant strategy to circumvent drug interactions and drugs with a poor metabolic tolerance profile.